Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

190.51 -4.05 (-2.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com, Ecopetrol, International Paper, Micron. 
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for... 
Via Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi... 
Via Talk Markets
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
From BeiGene, Ltd.
Via Business Wire
Evaluating BeiGene: Insights From 6 Financial Analysts
Via Benzinga
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
7 Large-Cap Stocks That Can Jump 50% By 2025
It isn't easy to find large-cap stocks offering 50% upside but that's exactly what this list provides for investors. 
Via InvestorPlace
Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululemon, Walgreens, and Li Auto. 
Via Benzinga
4 Analysts Assess BeiGene: What You Need To Know
Via Benzinga
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading
Via Investor Brand Network
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Via Talk Markets
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
From BeiGene, Ltd.
Via Business Wire
BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024
BGNE stock results show that BeiGene beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation. 
Via Benzinga
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
From BeiGene, Ltd.
Via Business Wire
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because... 
Via Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with... 
Via Benzinga
Exposures Product Safety
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
From BeiGene, Ltd.
Via Business Wire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
From BeiGene
Via Business Wire
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
Via Benzinga
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
Via Benzinga
Exposures Product Safety
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
From BeiGene, Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.